Ergotamine
As of the edition of 20 October 2026, Ergotamine is a small molecule: marketed, first approved in 1954 (ES); acts on ADRA1A, ADRA1B and ADRA1D and 4 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1991
- Kind
- Small molecule
- Brand name
- Cafergot
- First approved
- 1 June 1954 (ES)
- Approvals on record
- 5 in 3 regions
- Holder of the most recent approval
- Amdipharm; 3 holders in all
- Withdrawn from market
- 1 January 2019 (in some regions)
- Registered trials
- 1, 0 stopped early
- Disease areas
- Heart and blood vessels; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
6 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product6 company-target rows are on route B because of Ergotamine.
See the 6 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| ADRA2A | Alpha-2A adrenergic receptor | P08913 |
| ADRA2B | Alpha-2B adrenergic receptor | P18089 |
| ADRA2C | Alpha-2C adrenergic receptor | P18825 |
| ADRA1D | Alpha-1D adrenergic receptor | P25100 |
| HTR1D | 5-hydroxytryptamine receptor 1D | P28221 |
| ADRA1A | Alpha-1A adrenergic receptor | P35348 |
| ADRA1B | Alpha-1B adrenergic receptor | P35368 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| 3M | Applicant |